PMC:7161517 / 31050-31943 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T185","span":{"begin":0,"end":18},"obj":"Body_part"},{"id":"T186","span":{"begin":33,"end":37},"obj":"Body_part"},{"id":"T187","span":{"begin":98,"end":102},"obj":"Body_part"},{"id":"T188","span":{"begin":178,"end":183},"obj":"Body_part"},{"id":"T189","span":{"begin":241,"end":245},"obj":"Body_part"},{"id":"T190","span":{"begin":259,"end":263},"obj":"Body_part"},{"id":"T191","span":{"begin":341,"end":359},"obj":"Body_part"},{"id":"T192","span":{"begin":430,"end":437},"obj":"Body_part"},{"id":"T193","span":{"begin":459,"end":463},"obj":"Body_part"},{"id":"T194","span":{"begin":539,"end":543},"obj":"Body_part"}],"attributes":[{"id":"A185","pred":"fma_id","subj":"T185","obj":"http://purl.org/sig/ont/fma/fma82785"},{"id":"A186","pred":"fma_id","subj":"T186","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A187","pred":"fma_id","subj":"T187","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A188","pred":"fma_id","subj":"T188","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A189","pred":"fma_id","subj":"T189","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A190","pred":"fma_id","subj":"T190","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A191","pred":"fma_id","subj":"T191","obj":"http://purl.org/sig/ont/fma/fma82785"},{"id":"A192","pred":"fma_id","subj":"T192","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A193","pred":"fma_id","subj":"T193","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A194","pred":"fma_id","subj":"T194","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"Lipopolysaccharide-induced acute lung injury mouse models exhibited decreased expression of ACE2, lung and inflammatory injury; however, this was ameliorated by the injection of cells transfected with ACE2 and resulted in the improvement of lung function and lung injury. Treatment of these mice with ACE inhibitors and ARBs also alleviated lipopolysaccharide-induced pneumonic injury (67). Previous studies showed the SARS-CoV S protein can exaggerate acute lung failure through dysregulation of the RAS. However, SARS-CoV Spike–mediated lung failure could be rescued by inhibition of the AT1 receptor (67). Again, adequate data on the effects of RAS inhibition in patients with COVID-19 is not available, and ongoing clinical and/or observations studies are being conducted (see previous mentions of NCT04318301, NCT04318418, NCT04312009, NCT04311177, NCT04287686, NCT04330300, NCT04329195)."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T77","span":{"begin":33,"end":37},"obj":"Body_part"},{"id":"T78","span":{"begin":98,"end":102},"obj":"Body_part"},{"id":"T79","span":{"begin":241,"end":245},"obj":"Body_part"},{"id":"T80","span":{"begin":259,"end":263},"obj":"Body_part"},{"id":"T81","span":{"begin":459,"end":463},"obj":"Body_part"},{"id":"T82","span":{"begin":501,"end":504},"obj":"Body_part"},{"id":"T83","span":{"begin":539,"end":543},"obj":"Body_part"},{"id":"T84","span":{"begin":648,"end":651},"obj":"Body_part"}],"attributes":[{"id":"A77","pred":"uberon_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A78","pred":"uberon_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A79","pred":"uberon_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A80","pred":"uberon_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A81","pred":"uberon_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A82","pred":"uberon_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"},{"id":"A83","pred":"uberon_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A84","pred":"uberon_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"}],"text":"Lipopolysaccharide-induced acute lung injury mouse models exhibited decreased expression of ACE2, lung and inflammatory injury; however, this was ameliorated by the injection of cells transfected with ACE2 and resulted in the improvement of lung function and lung injury. Treatment of these mice with ACE inhibitors and ARBs also alleviated lipopolysaccharide-induced pneumonic injury (67). Previous studies showed the SARS-CoV S protein can exaggerate acute lung failure through dysregulation of the RAS. However, SARS-CoV Spike–mediated lung failure could be rescued by inhibition of the AT1 receptor (67). Again, adequate data on the effects of RAS inhibition in patients with COVID-19 is not available, and ongoing clinical and/or observations studies are being conducted (see previous mentions of NCT04318301, NCT04318418, NCT04312009, NCT04311177, NCT04287686, NCT04330300, NCT04329195)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T166","span":{"begin":27,"end":44},"obj":"Disease"},{"id":"T168","span":{"begin":38,"end":44},"obj":"Disease"},{"id":"T169","span":{"begin":120,"end":126},"obj":"Disease"},{"id":"T170","span":{"begin":264,"end":270},"obj":"Disease"},{"id":"T171","span":{"begin":378,"end":384},"obj":"Disease"},{"id":"T172","span":{"begin":419,"end":427},"obj":"Disease"},{"id":"T173","span":{"begin":515,"end":523},"obj":"Disease"},{"id":"T174","span":{"begin":590,"end":593},"obj":"Disease"},{"id":"T175","span":{"begin":680,"end":688},"obj":"Disease"}],"attributes":[{"id":"A166","pred":"mondo_id","subj":"T166","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A167","pred":"mondo_id","subj":"T166","obj":"http://purl.obolibrary.org/obo/MONDO_0015796"},{"id":"A168","pred":"mondo_id","subj":"T168","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A169","pred":"mondo_id","subj":"T169","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A170","pred":"mondo_id","subj":"T170","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A171","pred":"mondo_id","subj":"T171","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A172","pred":"mondo_id","subj":"T172","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A173","pred":"mondo_id","subj":"T173","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A174","pred":"mondo_id","subj":"T174","obj":"http://purl.obolibrary.org/obo/MONDO_0008840"},{"id":"A175","pred":"mondo_id","subj":"T175","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Lipopolysaccharide-induced acute lung injury mouse models exhibited decreased expression of ACE2, lung and inflammatory injury; however, this was ameliorated by the injection of cells transfected with ACE2 and resulted in the improvement of lung function and lung injury. Treatment of these mice with ACE inhibitors and ARBs also alleviated lipopolysaccharide-induced pneumonic injury (67). Previous studies showed the SARS-CoV S protein can exaggerate acute lung failure through dysregulation of the RAS. However, SARS-CoV Spike–mediated lung failure could be rescued by inhibition of the AT1 receptor (67). Again, adequate data on the effects of RAS inhibition in patients with COVID-19 is not available, and ongoing clinical and/or observations studies are being conducted (see previous mentions of NCT04318301, NCT04318418, NCT04312009, NCT04311177, NCT04287686, NCT04330300, NCT04329195)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T294","span":{"begin":33,"end":37},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T295","span":{"begin":33,"end":37},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T296","span":{"begin":45,"end":50},"obj":"http://purl.obolibrary.org/obo/CLO_0007836"},{"id":"T297","span":{"begin":98,"end":102},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T298","span":{"begin":98,"end":102},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T299","span":{"begin":178,"end":183},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T300","span":{"begin":241,"end":245},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T301","span":{"begin":241,"end":245},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T302","span":{"begin":259,"end":263},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T303","span":{"begin":259,"end":263},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T304","span":{"begin":459,"end":463},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T305","span":{"begin":459,"end":463},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T306","span":{"begin":539,"end":543},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T307","span":{"begin":539,"end":543},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"}],"text":"Lipopolysaccharide-induced acute lung injury mouse models exhibited decreased expression of ACE2, lung and inflammatory injury; however, this was ameliorated by the injection of cells transfected with ACE2 and resulted in the improvement of lung function and lung injury. Treatment of these mice with ACE inhibitors and ARBs also alleviated lipopolysaccharide-induced pneumonic injury (67). Previous studies showed the SARS-CoV S protein can exaggerate acute lung failure through dysregulation of the RAS. However, SARS-CoV Spike–mediated lung failure could be rescued by inhibition of the AT1 receptor (67). Again, adequate data on the effects of RAS inhibition in patients with COVID-19 is not available, and ongoing clinical and/or observations studies are being conducted (see previous mentions of NCT04318301, NCT04318418, NCT04312009, NCT04311177, NCT04287686, NCT04330300, NCT04329195)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T326","span":{"begin":0,"end":18},"obj":"Chemical"},{"id":"T328","span":{"begin":301,"end":315},"obj":"Chemical"},{"id":"T329","span":{"begin":305,"end":315},"obj":"Chemical"},{"id":"T330","span":{"begin":341,"end":359},"obj":"Chemical"},{"id":"T331","span":{"begin":430,"end":437},"obj":"Chemical"},{"id":"T332","span":{"begin":501,"end":504},"obj":"Chemical"},{"id":"T333","span":{"begin":648,"end":651},"obj":"Chemical"}],"attributes":[{"id":"A326","pred":"chebi_id","subj":"T326","obj":"http://purl.obolibrary.org/obo/CHEBI_16412"},{"id":"A327","pred":"chebi_id","subj":"T326","obj":"http://purl.obolibrary.org/obo/CHEBI_89981"},{"id":"A328","pred":"chebi_id","subj":"T328","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A329","pred":"chebi_id","subj":"T329","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A330","pred":"chebi_id","subj":"T330","obj":"http://purl.obolibrary.org/obo/CHEBI_16412"},{"id":"A331","pred":"chebi_id","subj":"T331","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A332","pred":"chebi_id","subj":"T332","obj":"http://purl.obolibrary.org/obo/CHEBI_63620"},{"id":"A333","pred":"chebi_id","subj":"T333","obj":"http://purl.obolibrary.org/obo/CHEBI_63620"}],"text":"Lipopolysaccharide-induced acute lung injury mouse models exhibited decreased expression of ACE2, lung and inflammatory injury; however, this was ameliorated by the injection of cells transfected with ACE2 and resulted in the improvement of lung function and lung injury. Treatment of these mice with ACE inhibitors and ARBs also alleviated lipopolysaccharide-induced pneumonic injury (67). Previous studies showed the SARS-CoV S protein can exaggerate acute lung failure through dysregulation of the RAS. However, SARS-CoV Spike–mediated lung failure could be rescued by inhibition of the AT1 receptor (67). Again, adequate data on the effects of RAS inhibition in patients with COVID-19 is not available, and ongoing clinical and/or observations studies are being conducted (see previous mentions of NCT04318301, NCT04318418, NCT04312009, NCT04311177, NCT04287686, NCT04330300, NCT04329195)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T189","span":{"begin":0,"end":271},"obj":"Sentence"},{"id":"T190","span":{"begin":272,"end":390},"obj":"Sentence"},{"id":"T191","span":{"begin":391,"end":505},"obj":"Sentence"},{"id":"T192","span":{"begin":506,"end":608},"obj":"Sentence"},{"id":"T193","span":{"begin":609,"end":893},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Lipopolysaccharide-induced acute lung injury mouse models exhibited decreased expression of ACE2, lung and inflammatory injury; however, this was ameliorated by the injection of cells transfected with ACE2 and resulted in the improvement of lung function and lung injury. Treatment of these mice with ACE inhibitors and ARBs also alleviated lipopolysaccharide-induced pneumonic injury (67). Previous studies showed the SARS-CoV S protein can exaggerate acute lung failure through dysregulation of the RAS. However, SARS-CoV Spike–mediated lung failure could be rescued by inhibition of the AT1 receptor (67). Again, adequate data on the effects of RAS inhibition in patients with COVID-19 is not available, and ongoing clinical and/or observations studies are being conducted (see previous mentions of NCT04318301, NCT04318418, NCT04312009, NCT04311177, NCT04287686, NCT04330300, NCT04329195)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T48","span":{"begin":27,"end":44},"obj":"Phenotype"}],"attributes":[{"id":"A48","pred":"hp_id","subj":"T48","obj":"http://www.orpha.net/ORDO/Orphanet_178320"}],"text":"Lipopolysaccharide-induced acute lung injury mouse models exhibited decreased expression of ACE2, lung and inflammatory injury; however, this was ameliorated by the injection of cells transfected with ACE2 and resulted in the improvement of lung function and lung injury. Treatment of these mice with ACE inhibitors and ARBs also alleviated lipopolysaccharide-induced pneumonic injury (67). Previous studies showed the SARS-CoV S protein can exaggerate acute lung failure through dysregulation of the RAS. However, SARS-CoV Spike–mediated lung failure could be rescued by inhibition of the AT1 receptor (67). Again, adequate data on the effects of RAS inhibition in patients with COVID-19 is not available, and ongoing clinical and/or observations studies are being conducted (see previous mentions of NCT04318301, NCT04318418, NCT04312009, NCT04311177, NCT04287686, NCT04330300, NCT04329195)."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T1012","span":{"begin":0,"end":18},"obj":"CHEBI:16412;CHEBI:16412"},{"id":"T1013","span":{"begin":33,"end":37},"obj":"UBERON:0002048"},{"id":"T1014","span":{"begin":45,"end":50},"obj":"NCBITaxon:10088"},{"id":"T1015","span":{"begin":78,"end":88},"obj":"GO:0010467"},{"id":"T1016","span":{"begin":92,"end":96},"obj":"G_3;PG_10;PR:000003622"},{"id":"T1017","span":{"begin":98,"end":102},"obj":"UBERON:0002048"},{"id":"T1018","span":{"begin":184,"end":195},"obj":"GO:0009294"},{"id":"T1019","span":{"begin":201,"end":205},"obj":"G_3;PG_10;PR:000003622"},{"id":"T1020","span":{"begin":241,"end":245},"obj":"UBERON:0002048"},{"id":"T1021","span":{"begin":259,"end":263},"obj":"UBERON:0002048"},{"id":"T1022","span":{"begin":291,"end":295},"obj":"NCBITaxon:10088"},{"id":"T1023","span":{"begin":305,"end":315},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T1024","span":{"begin":341,"end":359},"obj":"CHEBI:16412;CHEBI:16412"},{"id":"T1025","span":{"begin":368,"end":377},"obj":"UBERON:0006562"},{"id":"T1026","span":{"begin":419,"end":427},"obj":"SP_10"},{"id":"T1027","span":{"begin":428,"end":437},"obj":"PG_1"},{"id":"T1028","span":{"begin":459,"end":463},"obj":"UBERON:0002048"},{"id":"T1029","span":{"begin":480,"end":493},"obj":"GO:0065007"},{"id":"T1030","span":{"begin":515,"end":523},"obj":"SP_10"},{"id":"T1031","span":{"begin":539,"end":543},"obj":"UBERON:0002048"},{"id":"T1032","span":{"begin":590,"end":593},"obj":"PR:000001251"},{"id":"T1033","span":{"begin":680,"end":688},"obj":"SP_7"},{"id":"T45949","span":{"begin":0,"end":18},"obj":"CHEBI:16412;CHEBI:16412"},{"id":"T26573","span":{"begin":33,"end":37},"obj":"UBERON:0002048"},{"id":"T67408","span":{"begin":45,"end":50},"obj":"NCBITaxon:10088"},{"id":"T64221","span":{"begin":78,"end":88},"obj":"GO:0010467"},{"id":"T339","span":{"begin":92,"end":96},"obj":"G_3;PG_10;PR:000003622"},{"id":"T57577","span":{"begin":98,"end":102},"obj":"UBERON:0002048"},{"id":"T30771","span":{"begin":184,"end":195},"obj":"GO:0009294"},{"id":"T2102","span":{"begin":201,"end":205},"obj":"G_3;PG_10;PR:000003622"},{"id":"T26427","span":{"begin":241,"end":245},"obj":"UBERON:0002048"},{"id":"T88548","span":{"begin":259,"end":263},"obj":"UBERON:0002048"},{"id":"T40701","span":{"begin":291,"end":295},"obj":"NCBITaxon:10088"},{"id":"T25934","span":{"begin":305,"end":315},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T13796","span":{"begin":341,"end":359},"obj":"CHEBI:16412;CHEBI:16412"},{"id":"T57031","span":{"begin":368,"end":377},"obj":"UBERON:0006562"},{"id":"T56145","span":{"begin":419,"end":427},"obj":"SP_10"},{"id":"T3099","span":{"begin":428,"end":437},"obj":"PG_1"},{"id":"T33336","span":{"begin":459,"end":463},"obj":"UBERON:0002048"},{"id":"T48754","span":{"begin":480,"end":493},"obj":"GO:0065007"},{"id":"T39370","span":{"begin":515,"end":523},"obj":"SP_10"},{"id":"T41763","span":{"begin":539,"end":543},"obj":"UBERON:0002048"},{"id":"T35901","span":{"begin":590,"end":593},"obj":"PR:000001251"},{"id":"T86863","span":{"begin":680,"end":688},"obj":"SP_7"}],"text":"Lipopolysaccharide-induced acute lung injury mouse models exhibited decreased expression of ACE2, lung and inflammatory injury; however, this was ameliorated by the injection of cells transfected with ACE2 and resulted in the improvement of lung function and lung injury. Treatment of these mice with ACE inhibitors and ARBs also alleviated lipopolysaccharide-induced pneumonic injury (67). Previous studies showed the SARS-CoV S protein can exaggerate acute lung failure through dysregulation of the RAS. However, SARS-CoV Spike–mediated lung failure could be rescued by inhibition of the AT1 receptor (67). Again, adequate data on the effects of RAS inhibition in patients with COVID-19 is not available, and ongoing clinical and/or observations studies are being conducted (see previous mentions of NCT04318301, NCT04318418, NCT04312009, NCT04311177, NCT04287686, NCT04330300, NCT04329195)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1316","span":{"begin":92,"end":96},"obj":"Gene"},{"id":"1317","span":{"begin":201,"end":205},"obj":"Gene"},{"id":"1318","span":{"begin":301,"end":304},"obj":"Gene"},{"id":"1319","span":{"begin":45,"end":50},"obj":"Species"},{"id":"1320","span":{"begin":291,"end":295},"obj":"Species"},{"id":"1321","span":{"begin":419,"end":427},"obj":"Species"},{"id":"1322","span":{"begin":515,"end":523},"obj":"Species"},{"id":"1323","span":{"begin":666,"end":674},"obj":"Species"},{"id":"1324","span":{"begin":0,"end":18},"obj":"Chemical"},{"id":"1325","span":{"begin":341,"end":359},"obj":"Chemical"},{"id":"1326","span":{"begin":27,"end":44},"obj":"Disease"},{"id":"1327","span":{"begin":259,"end":270},"obj":"Disease"},{"id":"1328","span":{"begin":368,"end":384},"obj":"Disease"},{"id":"1329","span":{"begin":459,"end":471},"obj":"Disease"},{"id":"1330","span":{"begin":539,"end":551},"obj":"Disease"},{"id":"1331","span":{"begin":680,"end":688},"obj":"Disease"}],"attributes":[{"id":"A1316","pred":"tao:has_database_id","subj":"1316","obj":"Gene:70008"},{"id":"A1317","pred":"tao:has_database_id","subj":"1317","obj":"Gene:70008"},{"id":"A1318","pred":"tao:has_database_id","subj":"1318","obj":"Gene:11421"},{"id":"A1319","pred":"tao:has_database_id","subj":"1319","obj":"Tax:10090"},{"id":"A1320","pred":"tao:has_database_id","subj":"1320","obj":"Tax:10090"},{"id":"A1321","pred":"tao:has_database_id","subj":"1321","obj":"Tax:694009"},{"id":"A1322","pred":"tao:has_database_id","subj":"1322","obj":"Tax:694009"},{"id":"A1323","pred":"tao:has_database_id","subj":"1323","obj":"Tax:9606"},{"id":"A1324","pred":"tao:has_database_id","subj":"1324","obj":"MESH:D008070"},{"id":"A1325","pred":"tao:has_database_id","subj":"1325","obj":"MESH:D008070"},{"id":"A1326","pred":"tao:has_database_id","subj":"1326","obj":"MESH:D055371"},{"id":"A1327","pred":"tao:has_database_id","subj":"1327","obj":"MESH:D055370"},{"id":"A1328","pred":"tao:has_database_id","subj":"1328","obj":"MESH:D011014"},{"id":"A1329","pred":"tao:has_database_id","subj":"1329","obj":"MESH:D012131"},{"id":"A1330","pred":"tao:has_database_id","subj":"1330","obj":"MESH:D012131"},{"id":"A1331","pred":"tao:has_database_id","subj":"1331","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Lipopolysaccharide-induced acute lung injury mouse models exhibited decreased expression of ACE2, lung and inflammatory injury; however, this was ameliorated by the injection of cells transfected with ACE2 and resulted in the improvement of lung function and lung injury. Treatment of these mice with ACE inhibitors and ARBs also alleviated lipopolysaccharide-induced pneumonic injury (67). Previous studies showed the SARS-CoV S protein can exaggerate acute lung failure through dysregulation of the RAS. However, SARS-CoV Spike–mediated lung failure could be rescued by inhibition of the AT1 receptor (67). Again, adequate data on the effects of RAS inhibition in patients with COVID-19 is not available, and ongoing clinical and/or observations studies are being conducted (see previous mentions of NCT04318301, NCT04318418, NCT04312009, NCT04311177, NCT04287686, NCT04330300, NCT04329195)."}

{"project":"2_test","denotations":[{"id":"32305401-31805278-55253005","span":{"begin":386,"end":388},"obj":"31805278"},{"id":"32305401-31805278-55253006","span":{"begin":604,"end":606},"obj":"31805278"}],"text":"Lipopolysaccharide-induced acute lung injury mouse models exhibited decreased expression of ACE2, lung and inflammatory injury; however, this was ameliorated by the injection of cells transfected with ACE2 and resulted in the improvement of lung function and lung injury. Treatment of these mice with ACE inhibitors and ARBs also alleviated lipopolysaccharide-induced pneumonic injury (67). Previous studies showed the SARS-CoV S protein can exaggerate acute lung failure through dysregulation of the RAS. However, SARS-CoV Spike–mediated lung failure could be rescued by inhibition of the AT1 receptor (67). Again, adequate data on the effects of RAS inhibition in patients with COVID-19 is not available, and ongoing clinical and/or observations studies are being conducted (see previous mentions of NCT04318301, NCT04318418, NCT04312009, NCT04311177, NCT04287686, NCT04330300, NCT04329195)."}